Treg Therapy in Transplantation: How and When Will We Do It?

Abstract Adoptive therapy with regulatory T cells (Tregs) has shown great promises in many experimental models to induce permanent graft acceptance and tolerance to alloantigens. However, although their tolerogenic therapeutic potential has been demonstrated in clinical hematopoietic stem cell transplantation and partially in patients with early onset type I diabetes, translation into clinical testing for solid organ transplantation is still lacking or only slowly starting. This is in part due to the fact that many questions regarding not only the optimal type of Tregs but also the best-suited clinical trial design are unsolved and highly debated within the scientific community. With facilities for purifying and expanding Tregs and the clinical trials being very expensive, these points should be carefully discussed. Here, we summarized recent results regarding adoptive Treg therapy in solid organ transplantation additionally addressing the above-mentioned questions.
Source: Current Transplantation Reports - Category: Transplant Surgery Source Type: research